BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28465094)

  • 1. Enhancement of VP6 immunogenicity and protective efficacy against rotavirus by VP2 in a genetic immunization.
    Lopez-Guerrero DV; Arias N; Gutierrez-Xicotencatl L; Chihu-Amparan L; González A; Pedroza-Saavedra A; Rosas-Salgado G; Villegas-Garcia JC; Badillo-Godinez O; Fernandez G; Lopez S; Esquivel-Guadarrama F
    Vaccine; 2018 May; 36(22):3072-3078. PubMed ID: 28465094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of rotavirus VP6 to DEC-205 induces protection against the infection in mice.
    Badillo-Godinez O; Gutierrez-Xicotencatl L; Plett-Torres T; Pedroza-Saavedra A; Gonzalez-Jaimes A; Chihu-Amparan L; Maldonado-Gama M; Espino-Solis G; Bonifaz LC; Esquivel-Guadarrama F
    Vaccine; 2015 Aug; 33(35):4228-37. PubMed ID: 25850020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal immunization of mice with a rotavirus DNA vaccine that induces protective intestinal IgA antibodies.
    García-Díaz A; López-Andújar P; Rodríguez Díaz J; Montava R; Torres Barceló C; Ribes JM; Buesa J
    Vaccine; 2004 Dec; 23(4):489-98. PubMed ID: 15530697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved characteristics and protective efficacy in an animal model of E. coli-derived recombinant double-layered rotavirus virus-like particles.
    Li T; Lin H; Zhang Y; Li M; Wang D; Che Y; Zhu Y; Li S; Zhang J; Ge S; Zhao Q; Xia N
    Vaccine; 2014 Apr; 32(17):1921-31. PubMed ID: 24530406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Bacillus subtilis-based rotavirus vaccine.
    Lee S; Belitsky BR; Brinker JP; Kerstein KO; Brown DW; Clements JD; Keusch GT; Tzipori S; Sonenshein AL; Herrmann JE
    Clin Vaccine Immunol; 2010 Nov; 17(11):1647-55. PubMed ID: 20810679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
    Siadat-Pajouh M; Cai L
    Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotavirus capsid VP6 tubular and spherical nanostructures act as local adjuvants when co-delivered with norovirus VLPs.
    Malm M; Heinimäki S; Vesikari T; Blazevic V
    Clin Exp Immunol; 2017 Sep; 189(3):331-341. PubMed ID: 28407442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative immunogenicity in mice of rotavirus VP6 tubular structures and virus-like particles.
    Lappalainen S; Tamminen K; Vesikari T; Blazevic V
    Hum Vaccin Immunother; 2013 Sep; 9(9):1991-2001. PubMed ID: 23777748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Particle bombardment-mediated DNA vaccination with rotavirus VP6 induces high levels of serum rotavirus IgG but fails to protect mice against challenge.
    Choi AH; Knowlton DR; McNeal MM; Ward RL
    Virology; 1997 May; 232(1):129-38. PubMed ID: 9185596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine.
    Lappalainen S; Pastor AR; Malm M; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
    Arch Virol; 2015 Aug; 160(8):2075-8. PubMed ID: 26016444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The assembly conformation of rotavirus VP6 determines its protective efficacy against rotavirus challenge in mice.
    Pastor AR; Rodríguez-Limas WA; Contreras MA; Esquivel E; Esquivel-Guadarrama F; Ramírez OT; Palomares LA
    Vaccine; 2014 May; 32(24):2874-7. PubMed ID: 24583002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of gamma interferon and interleukin-17 production in intestinal CD4+ T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G).
    Smiley KL; McNeal MM; Basu M; Choi AH; Clements JD; Ward RL
    J Virol; 2007 Apr; 81(8):3740-8. PubMed ID: 17251301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human rotavirus virus-like particle vaccines evaluated in a neonatal gnotobiotic pig model of human rotavirus disease.
    Azevedo MP; Vlasova AN; Saif LJ
    Expert Rev Vaccines; 2013 Feb; 12(2):169-81. PubMed ID: 23414408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VP6: A candidate rotavirus vaccine.
    Ward RL; McNeal MM
    J Infect Dis; 2010 Sep; 202 Suppl():S101-7. PubMed ID: 20684688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrarectal immunization of mice with VP6 and either LT(R192G) or CTA1-DD as adjuvant protects against fecal rotavirus shedding after EDIM challenge.
    McNeal MM; Basu M; Bean JA; Clements JD; Lycke NY; Ramne A; Löwenadler B; Choi AH; Ward RL
    Vaccine; 2007 Aug; 25(33):6224-31. PubMed ID: 17629371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal or oral immunization of inbred and outbred mice with murine or human rotavirus VP6 proteins protects against viral shedding after challenge with murine rotaviruses.
    Choi AH; McNeal MM; Basu M; Flint JA; Stone SC; Clements JD; Bean JA; Poe SA; VanCott JL; Ward RL
    Vaccine; 2002 Sep; 20(27-28):3310-21. PubMed ID: 12213401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering and expression of a human rotavirus candidate vaccine in Nicotiana benthamiana.
    Pêra FF; Mutepfa DL; Khan AM; Els JH; Mbewana S; van Dijk AA; Rybicki EP; Hitzeroth II
    Virol J; 2015 Dec; 12():205. PubMed ID: 26626122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protection against rotavirus shedding after intranasal immunization of mice with a chimeric VP6 protein does not require intestinal IgA.
    McNeal MM; Stone SC; Basu M; Bean JA; Clements JD; Hendrickson BA; Choi AH; Ward RL
    Virology; 2006 Mar; 346(2):338-47. PubMed ID: 16375942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular cloning and immunogenicity evaluation of rotavirus structural proteins as candidate vaccine.
    El-Senousy WM; Shahein YE; Barakat AB; Ghanem HE; El-Hakim AE; Ameen SM
    Int J Biol Macromol; 2013 Aug; 59():67-71. PubMed ID: 23588003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo.
    Lappalainen S; Pastor AR; Tamminen K; López-Guerrero V; Esquivel-Guadarrama F; Palomares LA; Vesikari T; Blazevic V
    Hum Vaccin Immunother; 2014; 10(7):2039-47. PubMed ID: 25424814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.